Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial
Robert Sheppard Nickel(Children's National), Allistair Abraham(Children's National), Monica Bhatia(Columbia University Irving Medical Center), Jeremy Zack(Children's National), Vivitha Mani(Henry M. Jackson Foundation), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Sonali Chaudhury(Northwestern University), Gregory M.T. Guilcher(University of Calgary), Steven J. Hardy(NHS England), KY Chiang(Hospital for Sick Children), Michael Kent(Levine Children's Hospital)
Cited by 11
Related Papers
Lung adenocarcinoma promotion by air pollutants
|Nature|2023|751
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201
A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease
|Transplantation and Cellular Therapy|2020|201
Secondary solid cancer screening following hematopoietic cell transplantation
|Bone Marrow Transplantation|2015|186